Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Fluoropyrimidine-Associated Cardiotoxicity.

Kanduri J, More LA, Godishala A, Asnani A.

Cardiol Clin. 2019 Nov;37(4):399-405. doi: 10.1016/j.ccl.2019.07.004. Epub 2019 Aug 26. Review.

PMID:
31587781
2.

Changes in Citric Acid Cycle and Nucleoside Metabolism Are Associated with Anthracycline Cardiotoxicity in Patients with Breast Cancer.

Asnani A, Shi X, Farrell L, Lall R, Sebag IA, Plana JC, Gerszten RE, Scherrer-Crosbie M.

J Cardiovasc Transl Res. 2019 Jul 5. doi: 10.1007/s12265-019-09897-y. [Epub ahead of print]

PMID:
31278494
3.

Cardioprotection in cancer therapy: novel insights with anthracyclines.

Raber I, Asnani A.

Cardiovasc Res. 2019 Apr 15;115(5):915-921. doi: 10.1093/cvr/cvz023.

PMID:
30726931
4.

A novel network-based approach for discovering dynamic metabolic biomarkers in cardiovascular disease.

Baumgartner C, Spath-Blass V, Niederkofler V, Bergmoser K, Langthaler S, Lassnig A, Rienmüller T, Baumgartner D, Asnani A, Gerszten RE.

PLoS One. 2018 Dec 11;13(12):e0208953. doi: 10.1371/journal.pone.0208953. eCollection 2018.

5.

Cardiotoxicities associated with immune checkpoint inhibitors.

Yang S, Asnani A.

Curr Probl Cancer. 2018 Jul;42(4):422-432. doi: 10.1016/j.currproblcancer.2018.07.002. Epub 2018 Jul 18. Review.

PMID:
30173878
6.

The Antibacterial Activity of Dayak Onion (Eleutherine palmifolia (L.) Merr) towards Pathogenic Bacteria.

Harlita TD, Oedjijono, Asnani A.

Trop Life Sci Res. 2018 Jul;29(2):39-52. doi: 10.21315/tlsr2018.29.2.4. Epub 2018 Jul 6.

7.

Chest Pain During Chemotherapy: A Case of Severe Myocardial Bridging.

Mukhopadhyay A, Faridi KF, Asnani A, Osborn EA, Yang JX, Phillips CT, York M.

J Invasive Cardiol. 2018 Jul;30(7):E61.

8.

Biomarker Discovery in Cardio-Oncology.

Vohra A, Asnani A.

Curr Cardiol Rep. 2018 May 25;20(7):52. doi: 10.1007/s11886-018-1002-y. Review.

PMID:
29802472
9.

Beta-Blockers for Primary Prevention of Anthracycline Cardiotoxicity: Not Quite Ready for Prime Time.

Asnani A.

J Am Coll Cardiol. 2018 May 22;71(20):2291-2292. doi: 10.1016/j.jacc.2018.03.461. No abstract available.

10.

Cardiotoxicity of Immunotherapy: Incidence, Diagnosis, and Management.

Asnani A.

Curr Oncol Rep. 2018 Apr 11;20(6):44. doi: 10.1007/s11912-018-0690-1. Review.

PMID:
29644505
11.

Cardioprotection in the Modern Era of Cancer Chemotherapy.

Godishala A, Yang S, Asnani A.

Cardiol Rev. 2018 May/Jun;26(3):113-121. doi: 10.1097/CRD.0000000000000194. Review.

PMID:
29608498
12.

Highly potent visnagin derivatives inhibit Cyp1 and prevent doxorubicin cardiotoxicity.

Asnani A, Zheng B, Liu Y, Wang Y, Chen HH, Vohra A, Chi A, Cornella-Taracido I, Wang H, Johns DG, Sosnovik DE, Peterson RT.

JCI Insight. 2018 Jan 11;3(1). pii: 96753. doi: 10.1172/jci.insight.96753. eCollection 2018 Jan 11.

13.

Optimizing cardio-oncology programs for cancer patients.

Francis SA, Asnani A, Neilan T, Scherrer-Crosbie M.

Future Oncol. 2015;11(14):2011-5. doi: 10.2217/fon.15.128. No abstract available.

PMID:
26198828
14.

Roxithromycin potency quantification in pharmaceutical preparation by applying a validated bioassay method and comparison with HPLC analysis.

Suke SG, Chahande AD, Kasliwal RH, Asnani AJ.

Ann Pharm Fr. 2015 Sep;73(5):340-50. doi: 10.1016/j.pharma.2015.04.007. Epub 2015 May 26.

PMID:
26021576
15.

Visnagin protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase.

Liu Y, Asnani A, Zou L, Bentley VL, Yu M, Wang Y, Dellaire G, Sarkar KS, Dai M, Chen HH, Sosnovik DE, Shin JT, Haber DA, Berman JN, Chao W, Peterson RT.

Sci Transl Med. 2014 Dec 10;6(266):266ra170. doi: 10.1126/scitranslmed.3010189.

16.

The zebrafish as a tool to identify novel therapies for human cardiovascular disease.

Asnani A, Peterson RT.

Dis Model Mech. 2014 Jul;7(7):763-7. doi: 10.1242/dmm.016170. Review.

17.
18.

Status and prospects for discovery and verification of new biomarkers of cardiovascular disease by proteomics.

Gerszten RE, Asnani A, Carr SA.

Circ Res. 2011 Aug 5;109(4):463-74. doi: 10.1161/CIRCRESAHA.110.225003. Review.

19.

Synthesis of a BSA-Le(x) glycoconjugate and recognition of Le(x) analogues by the anti-Le(x) monoclonal antibody SH1: the identification of a non-cross reactive analogue.

Wang JW, Asnani A, Auzanneau FI.

Bioorg Med Chem. 2010 Oct 15;18(20):7174-85. doi: 10.1016/j.bmc.2010.08.040. Epub 2010 Aug 22.

PMID:
20843695
20.

Metabolic signatures of exercise in human plasma.

Lewis GD, Farrell L, Wood MJ, Martinovic M, Arany Z, Rowe GC, Souza A, Cheng S, McCabe EL, Yang E, Shi X, Deo R, Roth FP, Asnani A, Rhee EP, Systrom DM, Semigran MJ, Vasan RS, Carr SA, Wang TJ, Sabatine MS, Clish CB, Gerszten RE.

Sci Transl Med. 2010 May 26;2(33):33ra37. doi: 10.1126/scitranslmed.3001006.

21.

Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury.

Lewis GD, Wei R, Liu E, Yang E, Shi X, Martinovic M, Farrell L, Asnani A, Cyrille M, Ramanathan A, Shaham O, Berriz G, Lowry PA, Palacios IF, Taşan M, Roth FP, Min J, Baumgartner C, Keshishian H, Addona T, Mootha VK, Rosenzweig A, Carr SA, Fifer MA, Sabatine MS, Gerszten RE.

J Clin Invest. 2008 Oct;118(10):3503-12. doi: 10.1172/JCI35111.

22.

Application of metabolomics to cardiovascular biomarker and pathway discovery.

Lewis GD, Asnani A, Gerszten RE.

J Am Coll Cardiol. 2008 Jul 8;52(2):117-23. doi: 10.1016/j.jacc.2008.03.043. Review.

23.

Synthesis of Lewis X and three Lewis X trisaccharide analogues in which glucose and rhamnose replace N-acetylglucosamine and fucose, respectively.

Asnani A, Auzanneau FI.

Carbohydr Res. 2008 Jul 21;343(10-11):1653-64. doi: 10.1016/j.carres.2008.04.017. Epub 2008 Apr 22.

PMID:
18466887
24.

Antinociceptive activity of alcoholic extract of Hemidesmus indicus R.Br. in mice.

Verma PR, Joharapurkar AA, Chatpalliwar VA, Asnani AJ.

J Ethnopharmacol. 2005 Nov 14;102(2):298-301. Epub 2005 Aug 2.

PMID:
16081231
25.

Supplemental Content

Loading ...
Support Center